Compare Open Text Corporation (OTEX) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Open Text Corporation vs State Street SPDR S&P Biotech ETF — how do they compare? Open Text Corporation trades at $22.41 (market cap $5.54B), while State Street SPDR S&P Biotech ETF trades at $151.92. The key difference: Open Text Corporation pays a 4.83% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Open Text Corporation nearer its low. Which is the better fit depends on your goals.
| OTEX | XBI | |
|---|---|---|
Market Cap | $5.54B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $39.69 | $164.28 |
52-Week Low | $20.01 | $85.16 |
Enterprise Value | $10.70B | — |
Dividend Yield | 4.83% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Open Text Corporation (OTEX) trades at $23.33, up 0.26% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.01 surpassing expectations. Fundamentals show a P/E of 11.32 and net income margin of 9.91%, while recent news highlights a $105 million investment in European AI and cloud expansion.
The outlook for OTEX is positive, supported by value-oriented valuation, consistent earnings outperformance, and strategic investments in AI. Key risks include competitive pressures in software and execution of growth initiatives. Analyst consensus suggests a 30.7% upside to the $29.75 price target, with 42% of ratings being Buy.
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Open Text Corporation
Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Read more on OTEX →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
